Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal of Internal Medicine|October 27, 2020
On the relationship between BCG coverage and national COVID-19 outcome: could 'heterologous' herd immunity explain why some countries are better off?M LermJournal of Internal Medicine|May 28, 2018
Addressing diversity in tuberculosis using multidimensional approachesM Lerm, H M DockrellJournal of Internal Medicine|November 26, 2015
Trained immunity: a new avenue for tuberculosis vaccine developmentM Lerm, M G NeteaFEMS Microbiology Letters|June 27, 2000
Bacterial protein toxins targeting rho GTPasesM Lerm, G Schmidt, K AktoriesJournal of Internal Medicine|January 22, 2013
Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosisT Schön, M Lerm, O StendahlThe Journal of Biological Chemistry|June 5, 1998
The Rho-deamidating cytotoxic necrotizing factor 1 from Escherichia coli possesses transglutaminase activity. Cysteine 866 and histidine 881 are essential for enzyme activityG Schmidt, J Selzer, M Lerm, et al.The Journal of Biological Chemistry|November 5, 1999
Identification of the C-terminal part of Bordetella dermonecrotic toxin as a transglutaminase for rho GTPasesG Schmidt, U M Goehring, J Schirmer, et al.Thrombosis and Haemostasis|December 22, 2009
Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca2+ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activationH Kälvegren, C Skoglund, C Helldahl, et al.Infection and Immunity|April 20, 2006
Leishmania donovani requires functional Cdc42 and Rac1 to prevent phagosomal maturationM Lerm, A Holm, A Seiron, et al.Infection and Immunity|January 23, 1999
Deamidation of Cdc42 and Rac by Escherichia coli cytotoxic necrotizing factor 1: activation of c-Jun N-terminal kinase in HeLa cellsM Lerm, J Selzer, A Hoffmeyer, et al.Pageof 2